Extended Maintenance with Imatinib Enhances Disease-Free Survival in High-Risk GIST.

Published Date: 13 May 2024

DFS after three years was 87% after six years as opposed to 55% after three, but the toxicity was higher.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Firefighters who eat better can combat cancer.

2.

Active Surveillance Lawsuits; More Eligibility for Studies; Biosimilars Make News.

3.

November 2023, Medical Bulletin 04/.

4.

Multidrug Regimen Could Change Treatment Landscape for Relapsed/Refractory DLBCL

5.

Vepdegestrant Earns FDA Nod for ESR1-Mutated Breast Cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot